@article{TLCR28281,
author = {Gareth Rivalland and Paul Mitchell and Carmel Murone and Khashayer Asadi and Adrienne L. Morey and Maud Starmans and Paul C. Boutros and Marzena Walkiewicz and Benjamin Solomon and Gavin Wright and Simon Knight and Thomas John},
title = {Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {2},
year = {2019},
keywords = {},
abstract = {Background: In non-small cell lung cancer (NSCLC), mesenchyme to epithelial transition (MET) protein abundance increases with disease stage and is implicated in resistance to tyrosine kinase inhibitors. To better clarify the impact of MET overexpression on tumor behavior, we investigated a large cohort of patients who underwent curative surgical resection to determine whether MET gene amplification or protein abundance was prognostic.
Methods: Tissue microarrays (TMAs) were constructed using triplicate 1 mm cores of FFPE primary NSCLC specimens. TMAs underwent immunohistochemical (IHC) staining with the SP44 clone (Ventana) and cores were considered positive if >50% of tumor exhibited 2+ staining. The highest of triplicate values was used. MET gene amplification was detected using either SISH using Ventana’s MET DNP probe or FISH using the D7S486/CEP 7 Abbott Probe. DNA was subjected to mutational profiling using Sequenom’s LungCarta panel.
Results: Data from two institutions comprising 763 patients (516; 68%) male were generated, including 360 stage I, 226 stage II, 160 stage III and 18 resected stage IV. High MET protein expression was detected in 25% (193/763), and was significantly more common in adenocarcinomas than squamous cell carcinoma (P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/28281}
}